Reported about 9 hours ago
Hims & Hers saw its stock plunge 27% after announcing the potential cessation of some compounded weight-loss medications, raising investor fears about revenue losses in the GLP-1 segment. Despite a strong fourth quarter and positive revenue forecasts, concerns over the company’s weight-loss business overshadowed its broader subscriber base and other revenue streams. The stock, which had previously surged due to demand for semaglutide, struggled following FDA announcements regarding drug shortages.
Source: YAHOO